Mumbai: Piramal Pharma has set itself a target of reaching $2 billion in annual revenue with a 25% operating margin by fiscal 2030, largely led by its contract development and manufacturing organisation (CDMO) business. The Mumbai-based company is hoping to double its CDMO revenue by FY30. Piramal Pharma posted ₹8,171 crore ($987 million) of revenue in FY24, with CDMO contributing ₹4,750 crore, or 58%, to it.
Piramal Pharma is also gearing up to make strategic investments in the CDMO segment to fill capability gaps in active pharmaceutical ingredients, sterile manufacturing, biologics and antibody drug conjugates, among others. The company is also building peptide manufacturing capabilities to capture demand for GLP-1 weight loss drugs. "The focus will be on organic and brownfield expansion .
.. we plan each capex depending on customer demand and opportunity," chairperson Nandini Piramal told ET.
Potential acquisitions to boost the CDMO business will be based on opportunities and cash flow situation, he said. Artificial Intelligence(AI) Java Programming with ChatGPT: Learn using Generative AI By - Metla Sudha Sekhar, Developer and Lead Instructor View Program Artificial Intelligence(AI) Basics of Generative AI : Unveiling Tomorrow's Innovations By - Metla Sudha Sekhar, Developer and Lead Instructor View Program Artificial Intelligence(AI) Generative AI for Dynamic Java Web Applications with ChatGPT By - Metla Sudha Sekhar, Developer and Lead Instructor View Program Artific.
